← Back to Search

Local Anesthetic

Group 1: Block with Ropivacaine + Dexamethasone for Postoperative Pain

Phase 3
Waitlist Available
Research Sponsored by Rothman Institute Orthopaedics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights

Study Summary

This trial is testing whether adding the steroid dexamethasone to a single injection of local anesthetic improves post-operative pain scores and reduces opioid use.

Eligible Conditions
  • Postoperative Pain
  • Distal Radius Fracture

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Postoperative pain control
Postoperative pain control #2 questionnaire

Trial Design

2Treatment groups
Active Control
Group I: Group 1: Block with Ropivacaine + DexamethasoneActive Control2 Interventions
Before surgery an ultrasound guided supraclavicular block with ropivacaine and 4 mg of dexamethasone will be administered
Group II: Group 2: Ropivacaine Block + IV DexamethasoneActive Control2 Interventions
Before surgery an ultrasound guided supraclavicular block with ropivacaine will be administered and patients will receive dexamethasone intravenously

Find a Location

Who is running the clinical trial?

Rothman Institute OrthopaedicsLead Sponsor
121 Previous Clinical Trials
21,528 Total Patients Enrolled
3 Trials studying Postoperative Pain
523 Patients Enrolled for Postoperative Pain

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any dangers associated with Group 1: Block with Ropivacaine + Dexamethasone?

"Group 1: Block with Ropivacaine + Dexamethasone has received a score of 3 for safety. This is due to the fact that Phase 3 trials have yielded some efficacy data in addition to multiple rounds of data that support safety."

Answered by AI
~16 spots leftby Apr 2025